close-icon

MHQ: Clinical IntelligencePowered by SurvivorNet

  • health-panel

    Medical History

  • clinical-trial

    Clinical Trials

    ?
Prefer to talk instead of typing?
close-icon

Answers offered are informational and do not constitute medical advice. Learn more

close-icon
Medical History

Review your patient’s information.

What is your gender?

What is your age?

close-icon
Clinical Trials

clinical-icon

filter

Clear List

Ask me anything about your health...

I’m listening

thinking

responding

close-icon close-icon
close-icon
close-icon
close-icon
left-icon Back to Results

Dr. Harold J. Burstein

ABOUT

Dr. Burstein is an internationally renowned breast cancer expert, who has led and participated in multiple clinical trials, and developed national and international breast cancer treatment guidelines.

Dr. Harold J. Burstein profile image

Published Articles

Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review: A Systematic Review and Meta-Analysis.- 2026 Jul 16
Now or later? Switching therapies in metastatic breast cancer.- 2026 Aug
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.- 2026 Jul
SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.- 2026 Jun 20
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.- 2026 Jun 1
Corrigendum to 'Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?': [Annals of Oncology. Volume 37, Issue 2, February 2026, Pages 133-135].- 2026 Apr 7
Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer-The Sooner, the Better?- 2026 Apr 1
Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.- 2026 Feb 18
Outcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution.- 2026 Jan 8
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.- 2025 Nov

Clinical Trials

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer
Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider